Procyon Advisors’s TherapeuticsMD TXMD Stock Holding History

Procyon Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-641	Closed	-$24K	–	349
2021 Q3	$24K	Hold	641	–	–	0.01%	316
2021 Q2	$38K	Buy	+641	New	+$38.8K	0.01%	290

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Procyon Advisors's TXMD Position: Q4 2021 in Review

Procyon Advisors sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 641 shares — an estimated $24K sold.

Procyon Advisors first reported a position in TXMD in Q2 2021 and held it in 2 quarters. The position peaked at $38K in Q2 2021. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

Procyon Advisors reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
Procyon Advisors sold 641 TherapeuticsMD shares in Q4 2021, an estimated $24K.
Procyon Advisors first reported a position in TherapeuticsMD in Q2 2021 and held it in 2 quarters.
Procyon Advisors's TherapeuticsMD position peaked at $38K in Q2 2021.
131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Procyon Advisors's 13F filing for Q4 2021, filed 18 Jan 2022.